Summary
President Donald Trump announced a new agreement with the pharmaceutical company AstraZeneca to offer cheaper prescription drugs directly to Americans. The deal is part of Trump's ongoing effort to lower medication costs in the U.S. AstraZeneca is the second company, following Pfizer, to join this initiative, aimed at reducing U.S. drug prices to levels seen in other developed countries.
Key Facts
- President Trump introduced a deal with AstraZeneca to cut prescription drug costs.
- The agreement aims to offer lower prices for medications directly to American consumers.
- Trump stated that some drug prices could be reduced by over 100%, with specific examples such as asthma inhalers potentially seeing a 654% discount.
- The plan is part of Trump's push for "most favored nations prices," similar to those in other developed countries.
- AstraZeneca is the second company, after Pfizer, to agree to this pricing strategy.
- AstraZeneca and Pfizer are participating in a new online marketplace called TrumpRx.
- Trump used tariff threats to push pharmaceutical companies to work with the U.S. government.
- AstraZeneca plans to invest $50 billion in U.S. facilities by 2030 and will build a new drug manufacturing center in Virginia.
